1 – 10 of 52
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
- 2021
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article
- 2018
-
Mark
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
(
- Contribution to journal › Article
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
- 2015
-
Mark
Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
-
Mark
Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
-
Mark
Long-term retention of 177Lu/177mLu-Dotatate in patients investigated by gamma spectrometry and gamma camera imaging.
(
- Contribution to journal › Article
- 2014
-
Mark
Change in Cell Death Markers During (177)Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma.
(
- Contribution to journal › Article
-
Mark
Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article